Latest News for: nlrp3

Edit

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Nasdaq Globe Newswire 04 Dec 2025
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing ... .
Edit

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (Form 8-K) (Bioage Labs Inc)

Public Technologies 04 Dec 2025
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor ... BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 ... Background on BGE-102 and NLRP3.
Edit

AHA Scientific Sessions 2025 – Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation: A Novel Therapeutic Approach for Cardiovascular Inflammation (Monte Rosa Therapeutics Inc)

Public Technologies 08 Nov 2025
Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation ... Introduction to NEK7 in NLRP3 Inflammasome Activation ... NLRP3 ... Activation of the NLRP3. NLRP3 NEK7. NLRP3 ... NLRP3.
Edit

NLRP3 Protein Inhibitors Clinical Trials Analysis 2025: Competitive Landscape, Emerging Therapies, Leading Companies, and Future ...

GetNews 07 Oct 2025
In March 2024, Parkinson’s UK announced the investment of GBP 2.1 million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to ...
Edit

NLRP3 Protein Inhibitors Pipeline Drug Report 2025 Insights: Advancing Therapies, Drug Innovation, and Clinical Research

GetNews 06 Oct 2025
DelveInsight’s “NLRP3 Protein Inhibitors Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the NLRP3 Protein Inhibitors pipeline landscape ... NLRP3 Protein Inhibitors Overview.
  • 1
×